IS5329A - Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar - Google Patents
Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðarInfo
- Publication number
- IS5329A IS5329A IS5329A IS5329A IS5329A IS 5329 A IS5329 A IS 5329A IS 5329 A IS5329 A IS 5329A IS 5329 A IS5329 A IS 5329A IS 5329 A IS5329 A IS 5329A
- Authority
- IS
- Iceland
- Prior art keywords
- adjuvant
- monoglyceride
- transport system
- antigen
- antigen transport
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Cultivation Of Plants (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IS4518A IS4518A (is) | 1997-07-09 | 1997-07-09 | Nýtt lyfjaform fyrir bóluefni |
PCT/IS1998/000006 WO1999002186A2 (en) | 1997-07-09 | 1998-07-09 | Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
IS5329A true IS5329A (is) | 1999-12-29 |
Family
ID=36699745
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS4518A IS4518A (is) | 1997-07-09 | 1997-07-09 | Nýtt lyfjaform fyrir bóluefni |
IS5329A IS5329A (is) | 1997-07-09 | 1999-12-29 | Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS4518A IS4518A (is) | 1997-07-09 | 1997-07-09 | Nýtt lyfjaform fyrir bóluefni |
Country Status (13)
Country | Link |
---|---|
US (2) | US6514503B1 (is) |
EP (1) | EP1003551B1 (is) |
JP (1) | JP2001509491A (is) |
KR (1) | KR20010021622A (is) |
CN (1) | CN1202863C (is) |
AT (1) | ATE329617T1 (is) |
AU (1) | AU745849B2 (is) |
BR (1) | BR9810568A (is) |
CA (1) | CA2295237A1 (is) |
DE (1) | DE69834921T2 (is) |
ES (1) | ES2267189T3 (is) |
IS (2) | IS4518A (is) |
WO (1) | WO1999002186A2 (is) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IS4518A (is) * | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
ES2296390T3 (es) * | 1998-05-07 | 2008-04-16 | Corixa Corporation | Composicion coadyuvante y procedimiento para su uso. |
HUP0201220A3 (en) | 1999-05-13 | 2004-07-28 | Wyeth Holdings Corp Madison | Adjuvant combination formulations |
EP1212086B8 (en) * | 1999-08-18 | 2008-01-02 | Industry-Academic Cooperation Foundation, The Catholic University of Korea | Immunological tolerance-induction agent |
US7384640B1 (en) * | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
GB0007465D0 (en) * | 2000-03-29 | 2000-05-17 | Amersham Pharm Biotech Uk Ltd | Substrate for a lipase enzyme assay |
BR0111834A (pt) * | 2000-06-22 | 2003-07-08 | American Cyanamid Co | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno |
KR100863368B1 (ko) * | 2000-11-10 | 2008-10-13 | 와이어쓰 홀딩스 코포레이션 | 조합 보조 제제 |
ATE451386T1 (de) * | 2001-06-07 | 2009-12-15 | Wyeth Corp | Mutantenformen von cholera holotoxin als adjuvans |
WO2002098369A2 (en) * | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
CA2457595A1 (en) * | 2001-08-16 | 2003-02-27 | Lyfjathroun H.F., Biopharmaceuticals | A method of producing antibodies ex-vivo |
AU2002362039B2 (en) * | 2001-12-03 | 2007-07-26 | Soligenix, Inc | Stabilized reverse micelle compositions and uses thereof |
EP1476183A1 (en) * | 2002-02-25 | 2004-11-17 | Lyfjathroun HF, Biopharmaceutical Research | An immunological adjuvant |
AU2003215885B2 (en) * | 2002-02-25 | 2008-07-03 | Lyfjathroun Hf | Absorption enhancing agent |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
WO2004046693A1 (ja) * | 2002-11-21 | 2004-06-03 | Sapporo Immuno Diagnostic Laboratory | 唾液の採取および回収器具 |
AU2003299722A1 (en) * | 2002-12-17 | 2004-07-14 | Mdrna, Inc. | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
US8685718B2 (en) * | 2003-05-20 | 2014-04-01 | New York University | Mucosal immunization to prevent prion infection |
WO2005019412A2 (en) | 2003-05-20 | 2005-03-03 | New York University | Mucosal immunization to prevent prion infection |
US20060264505A1 (en) * | 2003-11-07 | 2006-11-23 | Stiefel Laboratories, Inc. | Dermatological compositions |
US20050100621A1 (en) * | 2003-11-07 | 2005-05-12 | Popp Karl F. | Dermatological compositions |
CN102861325A (zh) * | 2003-11-10 | 2013-01-09 | Uab研究基金会 | 减少细菌携带和中枢神经系统侵害的组合物及其使用方法 |
DE602006020738D1 (de) | 2005-08-01 | 2011-04-28 | Hisamitsu Pharmaceutical Co | Adjuvans oder pharmazeutische zubereitung zur transdermalen oder transmukosalen verabreichung |
AU2007285775B2 (en) * | 2006-08-17 | 2011-03-03 | Sanofi Pasteur Ltd. | Immunogenic PcpA polypeptides and uses thereof |
EP2123296B1 (en) * | 2007-01-31 | 2019-05-22 | Hisamitsu Pharmaceutical Co., Inc. | Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same |
AU2007353789B2 (en) * | 2007-05-23 | 2014-05-22 | The Uab Research Foundation | Detoxified pneumococcal neuraminidase and uses thereof |
US20120135039A1 (en) * | 2008-10-08 | 2012-05-31 | Aldwell Frank E | Oral Vaccines for Producing Mucosal Immunity |
CN106386848B (zh) * | 2009-03-11 | 2022-01-11 | 阿克苏诺贝尔化学品国际有限公司 | 包含草甘膦和烷氧基化甘油酯的除草配制剂 |
ES2588183T3 (es) * | 2009-03-31 | 2016-10-31 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
ES2744454T3 (es) | 2013-10-31 | 2020-02-25 | Hisamitsu Pharmaceutical Co | Composición de adyuvante |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE545978A (is) * | 1955-03-11 | |||
FR2253499B1 (is) * | 1973-12-10 | 1977-11-04 | Fabre Sa Pierre | |
US4420484A (en) | 1979-08-13 | 1983-12-13 | Sterling Drug Inc. | Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use therof |
DE3225706C2 (de) * | 1982-07-09 | 1984-04-26 | A. Nattermann & Cie GmbH, 5000 Köln | Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen |
JPS60149510A (ja) | 1984-01-13 | 1985-08-07 | Kao Corp | 農薬組成物 |
US4610868A (en) | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4771571A (en) * | 1986-12-31 | 1988-09-20 | Nabisco Brands, Inc. | Method for treating pineapple to prevent pineapple fruit diseases |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
EP0324455A3 (en) | 1988-01-15 | 1991-03-27 | Hans O. Ribi | Novel polymeric immunological adjuvants |
US5190748A (en) * | 1988-11-22 | 1993-03-02 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
US5177091A (en) * | 1990-12-06 | 1993-01-05 | Ciba-Geigy Corporation | Use of carbazones as novel active ingredients in medicaments |
SG47099A1 (en) * | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
WO1992018147A1 (en) * | 1991-04-19 | 1992-10-29 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
CA2083553A1 (en) | 1991-11-25 | 1993-05-26 | Kuniharu Seki | Immunogen composition |
GB9207799D0 (en) * | 1992-04-09 | 1992-05-27 | Procter & Gamble | Aqueous compositions |
US5314685A (en) * | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
AU679013B2 (en) * | 1992-10-16 | 1997-06-19 | Ibah, Inc. | Convertible microemulsion formulations |
IT1255895B (it) * | 1992-10-20 | 1995-11-17 | Laura Chiodini | Composizioni farmaceutiche contenenti una calcitonina |
CA2153780C (en) * | 1993-01-15 | 2004-04-13 | Micro Vesicular Systems, Inc. | Method of inhibiting viral reproduction |
DK17093D0 (da) * | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
KR100422191B1 (ko) * | 1994-08-05 | 2004-05-20 | 인파머 에스. 에이. | 포스페티딜콜린과착물화된프로스타글란딘e1및/또는트록세루틴을함유하는발기불능국부치료용조성물 |
FR2729307B1 (fr) * | 1995-01-18 | 1997-04-18 | Seppic Sa | Utilisation d'esters d'acides gras ethoxyles comme composants auto-emulsionnables notamment utiles pour la preparation de produits de traitement phytosanitaires ou de medicaments a usage veterinaire ou humain |
US5744137A (en) * | 1995-02-06 | 1998-04-28 | The United States Of America As Represented By The Secretary Of The Agriculture | Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants |
US6008228A (en) * | 1995-06-06 | 1999-12-28 | Hoffman-La Roche Inc. | Pharmaceutical compositions containing proteinase inhibitors |
AU718160B2 (en) * | 1995-06-09 | 2000-04-06 | R.P. Scherer Corporation | Soft gelatin capsules containing particulate material |
TW410158B (en) * | 1995-11-30 | 2000-11-01 | Chemo Sero Therapeut Res Inst | Oil adjuvant vaccine and method for preparing same |
SE9602280D0 (sv) * | 1996-06-10 | 1996-06-10 | Pharmatrix Ab | Immunstimulerande lipidformulering |
AU3868997A (en) * | 1996-08-26 | 1998-03-19 | Takeda Chemical Industries Ltd. | Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol |
IS4518A (is) * | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
FR2773489B1 (fr) * | 1998-01-15 | 2001-03-23 | Immunotech Sa | Nouvelle composition destinee a la voie oromuqueuse notamment pernasale |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
EP1034792A1 (en) * | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Intranasal delivery of pneumococcal polysaccharide vaccines |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
US6495596B1 (en) * | 2001-03-23 | 2002-12-17 | Biozibe Laboratories, Inc. | Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2 |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
-
1997
- 1997-07-09 IS IS4518A patent/IS4518A/is unknown
-
1998
- 1998-07-09 US US09/112,684 patent/US6514503B1/en not_active Expired - Fee Related
- 1998-07-09 WO PCT/IS1998/000006 patent/WO1999002186A2/en active IP Right Grant
- 1998-07-09 CA CA002295237A patent/CA2295237A1/en not_active Abandoned
- 1998-07-09 AU AU84598/98A patent/AU745849B2/en not_active Ceased
- 1998-07-09 BR BR9810568-0A patent/BR9810568A/pt not_active Application Discontinuation
- 1998-07-09 ES ES98935262T patent/ES2267189T3/es not_active Expired - Lifetime
- 1998-07-09 DE DE69834921T patent/DE69834921T2/de not_active Expired - Fee Related
- 1998-07-09 CN CNB988069660A patent/CN1202863C/zh not_active Expired - Fee Related
- 1998-07-09 KR KR1020007000180A patent/KR20010021622A/ko not_active Application Discontinuation
- 1998-07-09 AT AT98935262T patent/ATE329617T1/de not_active IP Right Cessation
- 1998-07-09 EP EP98935262A patent/EP1003551B1/en not_active Expired - Lifetime
- 1998-07-09 JP JP2000501776A patent/JP2001509491A/ja active Pending
-
1999
- 1999-12-29 IS IS5329A patent/IS5329A/is unknown
-
2002
- 2002-07-12 US US10/195,226 patent/US20030099659A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6514503B1 (en) | 2003-02-04 |
BR9810568A (pt) | 2000-09-19 |
CN1262626A (zh) | 2000-08-09 |
DE69834921T2 (de) | 2007-01-18 |
AU8459898A (en) | 1999-02-08 |
WO1999002186A2 (en) | 1999-01-21 |
CN1202863C (zh) | 2005-05-25 |
EP1003551B1 (en) | 2006-06-14 |
EP1003551A2 (en) | 2000-05-31 |
WO1999002186A3 (en) | 1999-04-01 |
JP2001509491A (ja) | 2001-07-24 |
DE69834921D1 (de) | 2006-07-27 |
US20030099659A1 (en) | 2003-05-29 |
ES2267189T3 (es) | 2007-03-01 |
IS4518A (is) | 1999-01-10 |
ATE329617T1 (de) | 2006-07-15 |
CA2295237A1 (en) | 1999-01-21 |
KR20010021622A (ko) | 2001-03-15 |
AU745849B2 (en) | 2002-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS5329A (is) | Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar | |
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
GB9808327D0 (en) | Antidiotypic compounds | |
EP0955059A3 (en) | Vaccines containing a saponin and a sterol | |
WO2001081609A3 (en) | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems | |
NZ532665A (en) | Neisseria meningitidis antigens and compositions | |
AR025750A1 (es) | Vacunas | |
NO982497D0 (no) | Vaksine-sammensetninger for inntak gjennom nesen | |
CY1108074T1 (el) | Ανοσολογικες μεθοδοι για τη ρυθμιση της μυοστατινης σε σπονδυλωτα | |
ATE501726T1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
WO2000002522A3 (en) | Anthrax vaccine | |
EP2246067A3 (en) | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes | |
TR200101256T2 (tr) | DNA ile aşılamada geliştirmeler | |
WO2004075829A3 (en) | Adjuvanted influenza vaccine | |
NO20005672L (no) | Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet | |
EP2275128A3 (en) | Protein-based streptococcus pneumoniae vaccines | |
SE9600647D0 (sv) | Ny användning | |
DZ2283A1 (fr) | Composition de vaccin. | |
NO20023935L (no) | Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater | |
ES2177927T3 (es) | Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico. | |
DE69836520D1 (de) | Clostridium perfringens Impfstoff | |
WO2004033483A3 (en) | Liposomal system and method of using same | |
WO1999012945A3 (en) | Hydrophobic glycosylamine derivatives, compositions, and methods for use | |
WO2004043141A3 (en) | Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians | |
WO1999016466A3 (en) | Vaccine compositions and methods of enhancing vaccine efficacy |